Your session is about to expire
← Back to Search
Avalglucosidase alfa (GZ402666) for Pompe Disease (COMET Trial)
COMET Trial Summary
This trial is looking at the effects of a drug called avalglucosidase alfa on people with a disease called Pompe. The trial will measure how well the drug works by looking at how it affects the patients' respiratory muscle strength and their ability to walk. The trial will also look at the safety of the drug and how it affects the patients' quality of life.
- Pompe Disease
COMET Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCOMET Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 100 Patients • NCT02782741COMET Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any historical precedence for Avalglucosidase alfa (GZ402666) in medical research?
"Avalglucosidase alfa (GZ402666) was first studied in 2014, and there have been 30 completed clinical trials to date. 8 of these studies are ongoing, with a majority taking place in Boston, Massachusetts."
Across how many distinct geographical areas is this experiment being conducted?
"There are 26 total investigational sites for this clinical trial, with Site Number 8400010 in Boston, Site Number 8400016 in Gainesville, and Site Number 8400018 in Salt Lake City being a few of them."
What other trials are similar to this one?
"Since 2014, Avalglucosidase alfa (GZ402666) has been studied in clinical trials. The first trial was completed in 2014 and was sponsored by Genzyme, a Sanofi company. After the initial study, which involved 19 patients, Avalglucosidase alfa (GZ402666) received approval for Phase 2 and 3 clinical trials. Today, there are 8 active trials for Avalglucosidase alfa (GZ402666) in 57 cities across 26 countries."
Has the FDA greenlit Avalglucosidase alfa (GZ402666)?
"Avalglucosidase alfa (GZ402666) has been given a score of 3 for safety. This is due to the fact that it is a Phase 3 trial, meaning that there is both supportive data for efficacy and rounds of data affirming its safety."
Share this study with friends
Copy Link
Messenger